NO20013100L - Sulfonamidhydroksamater - Google Patents

Sulfonamidhydroksamater

Info

Publication number
NO20013100L
NO20013100L NO20013100A NO20013100A NO20013100L NO 20013100 L NO20013100 L NO 20013100L NO 20013100 A NO20013100 A NO 20013100A NO 20013100 A NO20013100 A NO 20013100A NO 20013100 L NO20013100 L NO 20013100L
Authority
NO
Norway
Prior art keywords
sulfonamidhydroksamater
procollagen
char
proteinase
intermediates
Prior art date
Application number
NO20013100A
Other languages
English (en)
Norwegian (no)
Other versions
NO20013100D0 (no
Inventor
Roland Joseph Billedeau
Chris Allen Broka
Jeffrey Allen Campbell
Jian Jeffrey Chen
Sharon Marie Dankwardt
Nancy Delaet
Leslie Ann Robinson
Keith Adrian Murray Walker
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of NO20013100D0 publication Critical patent/NO20013100D0/no
Publication of NO20013100L publication Critical patent/NO20013100L/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D317/00Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/50Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to atoms of the carbocyclic ring
    • C07D317/58Radicals substituted by nitrogen atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/04Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/14Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/22Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
    • C07C311/23Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atoms of the sulfonamide groups bound to acyclic carbon atoms
    • C07C311/27Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atoms of the sulfonamide groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/08Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/10Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/12Radicals substituted by oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D235/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Detergent Compositions (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Hydrogenated Pyridines (AREA)
NO20013100A 1998-12-22 2001-06-21 Sulfonamidhydroksamater NO20013100L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11331198P 1998-12-22 1998-12-22
US14705399P 1999-08-03 1999-08-03
PCT/EP1999/009920 WO2000037436A1 (en) 1998-12-22 1999-12-14 Sulfonamide hydroxamates

Publications (2)

Publication Number Publication Date
NO20013100D0 NO20013100D0 (no) 2001-06-21
NO20013100L true NO20013100L (no) 2001-08-21

Family

ID=26810914

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20013100A NO20013100L (no) 1998-12-22 2001-06-21 Sulfonamidhydroksamater

Country Status (22)

Country Link
EP (1) EP1149072B1 (xx)
JP (1) JP2002533322A (xx)
KR (1) KR20010101312A (xx)
CN (1) CN1331674A (xx)
AT (1) ATE270271T1 (xx)
AU (1) AU769319B2 (xx)
BR (1) BR9916504A (xx)
CA (1) CA2355902A1 (xx)
CZ (1) CZ20012294A3 (xx)
DE (1) DE69918465D1 (xx)
HK (1) HK1042691A1 (xx)
HR (1) HRP20010443A2 (xx)
HU (1) HUP0104658A3 (xx)
IL (1) IL143625A0 (xx)
MA (1) MA26767A1 (xx)
NO (1) NO20013100L (xx)
NZ (1) NZ512292A (xx)
PL (1) PL349449A1 (xx)
RU (1) RU2232751C2 (xx)
TR (1) TR200101868T2 (xx)
WO (1) WO2000037436A1 (xx)
YU (1) YU44901A (xx)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0103303D0 (en) 2001-02-09 2001-03-28 Novartis Ag Organic compounds
GB0108097D0 (en) * 2001-03-30 2001-05-23 Pfizer Ltd Compounds
US6645993B2 (en) 2001-03-30 2003-11-11 Warner-Lambert Company 3-heterocyclylpropanohydroxamic acid PCP inhibitors
JP2005500287A (ja) * 2001-06-11 2005-01-06 シャイアー バイオケム インコーポレイテッド Flavivirus感染の処置または予防のための化合物および方法
CA2479906C (en) 2002-04-03 2011-02-08 Topotarget Uk Limited Carbamic acid compounds comprising a piperazine linkage as hdac inhibitors
MXPA05008106A (es) * 2003-02-18 2005-09-21 Pfizer Inhibidores del virus de la hepatitis c, composiciones y tratamientos que los emplean.
WO2005023257A1 (en) * 2003-09-03 2005-03-17 Glaxo Group Limited Novel process, salts, compositions and use
US7342039B2 (en) * 2003-09-25 2008-03-11 Wyeth Substituted indole oximes
NZ549962A (en) * 2004-03-16 2010-04-30 Univ Temple Substituted phenoxy-and phenylthio-derivatives for treating proliferative disorders
ITFI20040174A1 (it) * 2004-08-03 2004-11-03 Protera S R L Derivati arilsolfonammidici dell'acido idrossammico ad azione inibitoria di metalloproteinasi
WO2010007027A1 (en) * 2008-07-14 2010-01-21 Novartis Ag Selective hydroxamic acid based mmp-12 and mmp-13 inhibitors
US20100160322A1 (en) * 2008-12-04 2010-06-24 Abbott Laboratories Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
US8557983B2 (en) 2008-12-04 2013-10-15 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
US8586754B2 (en) 2008-12-05 2013-11-19 Abbvie Inc. BCL-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases
US8563735B2 (en) 2008-12-05 2013-10-22 Abbvie Inc. Bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases
FR2947268B1 (fr) 2009-06-30 2011-08-26 Galderma Res & Dev Nouveaux composes benzene-sulfonamides, leur procede de synthese et leur utilisation en medecine ainsi qu'en cosmetique
US8354548B2 (en) * 2010-02-19 2013-01-15 Bristol-Myers Squibb Company Glycine chroman-6-sulfonamides for use as inhibitors of diacylglycerol lipase
JPWO2012165262A1 (ja) * 2011-05-27 2015-02-23 国立大学法人徳島大学 ベンジルアミン誘導体
AU2015205370B2 (en) 2014-01-10 2017-11-30 Glaxosmithkline Intellectual Property (No.2) Limited Hydroxy formamide derivatives and their use

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5455258A (en) * 1993-01-06 1995-10-03 Ciba-Geigy Corporation Arylsulfonamido-substituted hydroxamic acids
KR19990036271A (ko) * 1995-08-08 1999-05-25 토마스 네프 콜라겐 과다생산과 연관된 질환의 치료에 이용되는 c-프로테나제 저해물질

Also Published As

Publication number Publication date
RU2232751C2 (ru) 2004-07-20
NO20013100D0 (no) 2001-06-21
ATE270271T1 (de) 2004-07-15
CA2355902A1 (en) 2000-06-29
IL143625A0 (en) 2002-04-21
KR20010101312A (ko) 2001-11-14
AU769319B2 (en) 2004-01-22
NZ512292A (en) 2004-03-26
WO2000037436A1 (en) 2000-06-29
HK1042691A1 (zh) 2002-08-23
PL349449A1 (en) 2002-07-29
MA26767A1 (fr) 2004-12-20
HUP0104658A3 (en) 2005-12-28
EP1149072B1 (en) 2004-06-30
CN1331674A (zh) 2002-01-16
CZ20012294A3 (cs) 2001-12-12
AU1979200A (en) 2000-07-12
TR200101868T2 (tr) 2001-11-21
DE69918465D1 (de) 2004-08-05
BR9916504A (pt) 2001-09-11
YU44901A (sh) 2003-12-31
HUP0104658A2 (en) 2002-06-29
EP1149072A1 (en) 2001-10-31
HRP20010443A2 (en) 2002-06-30
JP2002533322A (ja) 2002-10-08

Similar Documents

Publication Publication Date Title
DE69918465D1 (de) Sulfonamidhydroxamate
ATE253545T1 (de) Biarylessigsäure-derivate und ihre verwendung als cox-2 inhibitoren
EA200201179A1 (ru) Производные 2-аминокарбонил-9h-пурина
EA200200940A1 (ru) Производные азетидина, способ их получения и содержащие их фармацевтические композиции
EA200200938A1 (ru) Фармацевтические композиции, содержащие производные азетидина, новые производные азетидина и их получение
EA200200770A1 (ru) Производные пурина
DK0889876T3 (da) Meta-substituerede phenylensulfonamidderivater
UY25204A1 (es) Agonistas de prostaglandinas útiles en el tratamiento de desórdenes óseos
IL135536A0 (en) Ortho-anthranilamide derivatives and pharmaceutical compositions containing the same
FI842419A (fi) 2-pyrimidinyl-1-piperazin-derivat, foerfarande foer deras framstaellning och dessa innehaollande laekemedel.
NO20060154L (no) Imidazolyl-derivater
EA200000334A1 (ru) Производные карбоксамидотиазолов, их получение, содержащие их фармацевтические композиции
EA200300453A1 (ru) Производные 3-ароилиндола и их применение в качестве агонистов рецепторов cb2
DK1140918T3 (da) Thrombininhibitorer
FI970317A0 (fi) Antiproliferatiivisina aineina ja Garft-inhibiittoreina käyttökelpoisia yhdisteitä
EA200200912A1 (ru) Новые производные индолин-2-она, их получение и их применение в качестве лигандов рецепторов окситоцина
TR200101663T2 (tr) Pro-kollajen c-proteinaz inhibitörleri
EA200200774A1 (ru) Новые соединения, обладающие гиполипидемической, гипохолестеринемической активностью, способ их получения и содержащие их композиции
DE60336735D1 (de) Neue biologischaktive molekü le
EA200400454A1 (ru) Мускариновые агонисты
EA200301317A1 (ru) Производные аминохинолина и его применение в качестве лигандов аденозина a3
MXPA04006113A (es) Derivados de triazoloquinolina utiles como ligandos receptores de adenosina.
DK1102765T3 (da) Fremgangsmåde til syntese af (1H)-benzo[c]quinolizin-3-on-derivater
NO20022977D0 (no) Substituerte homopiperidinylbenzimidazolanaloger som fundiske relaksanter
FI963168A (fi) Enkefalinaasin inhibiittoreina käyttökelpoisia uusia indaani-2-merkaptoasetyyliamiddisulfidijohdannaisia

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application